The potential sale of its 88% stake in Bausch + Lomb could generate billions for creditors and shareholders of the indebted ...

Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 ...

Bausch Health has recently changed its strategy for Bausch + Lomb, looking to sell the segment which has a market capitalization of nearly $8 billion. The potential sale of Bausch + Lomb is a break ...

Shares of contact lens supplier Bausch + Lomb ($BLCO) are surging in today’s trading amid news of a potential acquisition.

Evercore ISI upgraded shares of Bausch Health Companies (TSE:BHC – Free Report) to a hold rating in a research note published ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Bausch Health (NYSE: BHC) stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb ...

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Bausch Health Companies Inc. ( NYSE:BHC ) shareholders should be happy to see the share price up 26% in the last ...

Health-care companies rose slightly amid mixed earnings. CVS Health replaced its top executive as it warned that its coming earnings will once again fall short of Wall Street expectations, sending ...

In a report released today, Umer Raffat from Evercore ISI maintained a Hold rating on Bausch Health Companies (BHC – Research Report).

Evercore ISI upgraded shares of Bausch + Lomb (NYSE:BLCO – Free Report) from an in-line rating to an outperform rating in a ...